The introduction of the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
regimen 30 years ago was the great breakthrough in the treatment of advanced-stage …

Background The addition of etoposide to combination chemotherapy with
cyclophosphamide, doxorubicin, vincristine and prednisone [etoposide to combination …

Hematologic toxicities of cancer chemotherapy are common and often limit the ability to
provide treatment in a timely and dose-intensive manner. These limitations may be of utmost …

Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an …

A single center, prospective clinical trial was conducted evaluating 2 cycles of induction high-
dose chemotherapy for adults younger than 65 years of age with aggressive non-Hodgkin …

The identification of refractory or nonresponding tumors at an early period during therapy
may lead to abbreviation of the current therapy regimen or timely institution of an alternative …

The CHOP (cyclophosphamide/doxorucibin/vincristine/prednisone) regimen has been
established as the standard treatment for diffuse large B-cell lymphoma (DLBCL). With the …

Less than a decade ago, one would begin such a paper stating that non-Hodgkin's
lymphomas (NHL) are treated with chemotherapy, radiation and steroids and that …

To improve the clinical outcomes of patients with hematologic and solid tumor malignancies,
the trend in oncology has been to capitalize on the concept of dose intensity. The data …

ABSTRACT A single centre, prospective clinical trial was conducted evaluating two cycles of
induction high dose chemotherapy for adults less than 65 years of age with aggressive non …